article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 On the report’s findings, Steve Bates OBE, CEO of the BIA, said: “UK-based life sciences companies are worldleading in developing life changing medical innovation.

article thumbnail

STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case

STAT

In the second-largest fine ever levied on a pharmaceutical company, Endo Health Solutions was ordered to pay nearly $1.1 billion in criminal penalties and another $450 million in criminal forfeiture for illegally marketing its Opana ER prescription opioid.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

According to the Janssen Pharmaceutical Companies of Johnson & Johnson and NICE, DVCd is recommended for the rare bone marrow disorder, only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses.

article thumbnail

Opinion: STAT+: What Mark Cuban gets wrong about prescription drugs

STAT

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. Meanwhile, generic drug companies saved the U.S. But that might not be the case.

article thumbnail

Gilead wins patent battle with US government over HIV PrEP drugs

Pharmaceutical Technology

This marks a significant development in a tumultuous dispute between the pharmaceutical company and the US government. In November 2019, the government sued Gilead over the company’s alleged patent infringement of the two PrEP drugs Descovy and Truvada. Gilead markets both Truvada and its successor Descovy.

article thumbnail

Eczac?ba?? to acquire Turkish pharma company Gensenta for $135m

Pharmaceutical Technology

Group has entered an agreement for the acquisition of a 99.96% stake in Turkish pharmaceutical company Gensenta from Amgen, in a deal worth $135m. is the founder of the first modern pharmaceutical facility in Turkey. Amgen Turkey noted that the company will maintain its operations and serve its patients in the region.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).

FDA 103